Cartesian Therapeutics (RNAC) Accumulated Expenses (2015 - 2026)

Cartesian Therapeutics (RNAC) has reported Accumulated Expenses for 12 consecutive years, with $10.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses rose 10.48% year-over-year to $10.2 million; the TTM figure through Mar 2026 stood at $10.2 million (up 10.48% YoY), while the FY2025 annual figure was $9.5 million, down 21.35% from the prior year.
• Accumulated Expenses grew to $10.2 million in Q1 2026 per RNAC's latest filing, from $9.5 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $15.6 million in Q4 2023 and bottomed at $7.7 million in Q3 2025.
• Historically, Accumulated Expenses has averaged $10.9 million across 5 years, with a median of $10.2 million in 2026.
• Annual changes were most pronounced in 2022 — Accumulated Expenses surged 39.56% — and 2024, when it tumbled 30.69%.
• Cartesian Therapeutics' Accumulated Expenses stood at $14.1 million in 2022, then rose by 10.57% to $15.6 million in 2023, then dropped by 22.45% to $12.1 million in 2024, then decreased by 21.35% to $9.5 million in 2025, then gained by 6.98% to $10.2 million in 2026.
• Business Quant data shows RNAC's Accumulated Expenses at $10.2 million in Q1 2026, $9.5 million in Q4 2025, and $7.7 million in Q3 2025.